Literature DB >> 11084219

Effect of venlafaxine on imipramine metabolism.

L J Albers1, C Reist, R L Vu, K Fujimoto, V Ozdemir, D Helmeste, R Poland, S W Tang.   

Abstract

The present study was designed to determine the effect of venlafaxine on imipramine metabolism in an attempt to elucidate the potential for cytochrome P450 drug-drug interactions with venlafaxine. We examined the metabolism of a single 100-mg dose of imipramine before and after treatment with venlafaxine, 50 mg three times a day. Eight male subjects were phenotyped for CYP2D6 activity. Two subjects were poor metabolizers of dextromethophan, and data from the remaining six subjects (mean age=45.3+/-15) were analyzed. Venlafaxine increased imipramine C(max) and elevated AUC by 40%. Desipramine clearance and volume of distribution were reduced by 20% and 25%, respectively. These findings are consistent with a statistically significant, but clinically modest impact of venlafaxine on CYP2D6-metabolized substrates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11084219     DOI: 10.1016/s0165-1781(00)00213-4

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  10 in total

Review 1.  Clinically significant drug interactions with newer antidepressants.

Authors:  Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

Review 2.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.

Authors:  P K Gillman
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

3.  In vivo information-guided prediction approach for assessing the risks of drug-drug interactions associated with circulating inhibitory metabolites.

Authors:  Zhe-Yi Hu; Robert B Parker; S Casey Laizure
Journal:  Drug Metab Dispos       Date:  2012-05-04       Impact factor: 3.922

4.  Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.

Authors:  C K Yeung; Y Fujioka; H Hachad; R H Levy; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2010-12-01       Impact factor: 6.875

5.  Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants.

Authors:  Christian Puozzo; Simone Lens; Christian Reh; Karl Michaelis; Dominique Rosillon; Xavier Deroubaix; Dominique Deprez
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 6.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Authors:  V Craig Jordan
Journal:  Steroids       Date:  2007-07-27       Impact factor: 2.668

Review 7.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Getting the balance right: Established and emerging therapies for major depressive disorders.

Authors:  Bojana Perović; Marija Jovanović; Branislava Miljković; Sandra Vezmar
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

9.  Venlafaxine in the treatment of panic disorder.

Authors:  Martin A Katzman; Leslie Jacobs
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

10.  Prediction of Metabolite-to-Parent Drug Exposure: Derivation and Application of a Mechanistic Static Model.

Authors:  Ernesto Callegari; Manthena V S Varma; R Scott Obach
Journal:  Clin Transl Sci       Date:  2020-02-04       Impact factor: 4.689

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.